RxDoctor Payments Data

Charlene Lin, MD

Internal Medicine · Yorba Linda, CANPI 1447888375

Payments from drug & device makers

$1,345in general payments, 2019–2025

Across 35 payments — averaging $38.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$271
  • Novo Nordisk$268
  • Lilly USA, LLC$252
  • AstraZeneca$129
  • Abbott$121
  • Boston Scientific$119
  • plus $185 from 5 others

What the payments were for

  • Food & beverage$1,345100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,345 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$96,186
Medicare patients
308
Services billed
1,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$46,276
OzempicSemaglutide32$38,126
JardianceEmpagliflozin17$23,691
XareltoRivaroxaban21$17,125
WegovySemaglutide13$15,999
JanuviaSitagliptin Phosphate15$12,124
EntrestoSacubitril/Valsartan13$8,464
SynthroidLevothyroxine Sodium34$2,719
Gabapentin84$1,982
Rosuvastatin Calcium134$1,867
Atorvastatin Calcium206$1,837
Levothyroxine Sodium149$1,719
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,652
Potassium Chloride35$1,487
Ezetimibe38$1,385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$268$54,12445 claims
PfizerEliquis$18$46,27651 claims
Boehringer IngelheimJardiance$271$23,69117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Yorba Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →